A 4-dose box of Vyleesi costs $99 without coverage[1]. That is $24.75 a dose. The price was read from the maker’s site in September 2026.
Vyleesi is the brand name for bremelanotide, sold elsewhere as PT-141. Why the compounded version is rarely priced up front is in the PT-141 cost guide.
$99
Vyleesi cash price, 4-dose box
Source: Vyleesi site
$24.75
Per dose, at that price
$198
A month at the label's 8-dose limit
$199
Typical compounded PT-141 month (37 sellers)
That puts the brand $1 below the typical compounded month. These are different products and quantities, not equivalent treatments. Seller prices were read through October 2026.
| Doses needed | Boxes purchased | Medication charge |
|---|---|---|
| 1–4 | 1 | $99 |
| 5–8 | 2 | $198 |
Unused doses can remain after a box purchase. The per-dose figure is arithmetic, not a fractional-box checkout price.
How the month is counted
Vyleesi is a single-dose autoinjector of 1.75 mg[2]. It is taken as needed, at least 45 minutes before sex[2]. Cash purchases come by the box, not by a fraction of a box.
The label caps that count. No more than one dose in 24 hours[2]. More than 8 doses a month is not recommended[2]. At the cap, you need 2 boxes, or $198.
Cartons come in 2 or 4 autoinjectors[2]. The $99 offer names the 4-dose box[1].
With commercial insurance
The maker says most commercially insured patients pay $0 for a box[1]. The fine print says “as little as”[1]. Each patient is assessed individually[1].
The help covers copay, coinsurance or deductible[1]. It applies to 2 fills every 30 days[1]. Two 4-dose fills match the label’s 8-dose month.
You must be 18 or older[1]. Enrollment cannot be backdated[1]. The maker may end or change the program at any time[1].
With Medicare or Medicaid
Government-insured patients are not eligible for the copay help[1]. Medicare Part D also excludes drugs used for sexual dysfunction[4]. The exception is a drug used for another approved condition[4].
Ask the pharmacy whether a cash option is available for your circumstances. General coverage rules are in the insurance guide.
Who is buying it
Vyleesi is approved for premenopausal women with acquired, generalized HSDD[2]. It is not indicated for postmenopausal women or men[2]. FDA approved it on June 21, 2019[3].
The label adds a stop rule. Stop after 8 weeks without improvement[2]. That reassessment does not establish a minimum purchase commitment.
How the prescription reaches you
The maker’s pharmacy partner handles the copay and applies the savings[1]. Delivery is free, per the maker[1]. How online prescribing works in general is in how online peptide therapy works.
Who can prescribe it is in PT 141 prescription.
Compounded sellers are ranked by monthly price on the PT-141 price board.